These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36471872)

  • 41. Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against Wuhan-WT, delta and omicron BA1, BA2 spike trimers.
    Cheedarla N; Verkerke HP; Potlapalli S; McLendon KB; Patel A; Frank F; O'Sick WH; Cheedarla S; Baugh TJ; Damhorst GL; Wu H; Graciaa D; Hudaib F; Alter DN; Bryksin J; Ortlund EA; Guarner J; Auld S; Shah S; Lam W; Mattoon D; Johnson JM; Wilson DH; Dhodapkar MV; Stowell SR; Neish AS; Roback JD
    iScience; 2023 Nov; 26(11):108256. PubMed ID: 37965140
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies.
    Li R; Mor M; Ma B; Clark AE; Alter J; Werbner M; Lee JC; Leibel SL; Carlin AF; Dessau M; Gal-Tanamy M; Croker BA; Xiang Y; Freund NT
    Commun Biol; 2022 Aug; 5(1):789. PubMed ID: 35931732
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination.
    Chi X; Guo Y; Zhang G; Sun H; Zhang J; Li M; Chen Z; Han J; Zhang Y; Zhang X; Fan P; Zhang Z; Wang B; Zai X; Han X; Hao M; Fang T; Xu J; Wu S; Chen Y; Fang Y; Dong Y; Sun B; Zhang J; Li J; Zhao G; Yu C; Zhou Q; Chen W
    Signal Transduct Target Ther; 2022 Apr; 7(1):139. PubMed ID: 35478188
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
    Harvala H; Nguyen D; Simmonds P; Lamikanra AA; Tsang HP; Otter A; Maes P; Webster M; Clarkson A; Kaloyirou F; Hopkins V; Laidlaw SM; Carroll M; Mora A; Griffiths A; MacLennan S; Estcourt L; Roberts DJ
    Transfusion; 2022 Jul; 62(7):1347-1354. PubMed ID: 35588314
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.
    Li CJ; Chao TL; Chang TY; Hsiao CC; Lu DC; Chiang YW; Lai GC; Tsai YM; Fang JT; Ieong S; Wang JT; Chang SY; Chang SC
    Microbiol Spectr; 2022 Apr; 10(2):e0181421. PubMed ID: 35293796
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
    Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
    EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination.
    Hastert FD; Hein S; von Rhein C; Benz NI; Husria Y; Oberle D; Maier TJ; Hildt E; Schnierle BS
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632550
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron.
    Ma H; Zhang X; Zheng P; Dube PH; Zeng W; Chen S; Cheng Q; Yang Y; Wu Y; Zhou J; Hu X; Xiang Y; Zhang H; Chiu S; Jin T
    Cell Res; 2022 Sep; 32(9):831-842. PubMed ID: 35906408
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees.
    Andreano E; Paciello I; Marchese S; Donnici L; Pierleoni G; Piccini G; Manganaro N; Pantano E; Abbiento V; Pileri P; Benincasa L; Giglioli G; Leonardi M; Maes P; De Santi C; Sala C; Montomoli E; De Francesco R; Rappuoli R
    Nat Commun; 2022 Jun; 13(1):3375. PubMed ID: 35697673
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants.
    Liu C; Rcheulishvili N; Shen Z; Papukashvili D; Xie F; Wang Z; Wang X; He Y; Wang PG
    Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631687
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interaction analysis of SARS-CoV-2 omicron BA1 and BA2 of RBD with fifty monoclonal antibodies: Molecular dynamics approach.
    Sandhya KS; Kishore AA; Unni A; Sunitha P; Sajithra CV; Nair AS
    J Mol Graph Model; 2024 May; 128():108719. PubMed ID: 38324968
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD.
    Chen Y; Prévost J; Ullah I; Romero H; Lisi V; Tolbert WD; Grover JR; Ding S; Gong SY; Beaudoin-Bussières G; Gasser R; Benlarbi M; Vézina D; Anand SP; Chatterjee D; Goyette G; Grunst MW; Yang Z; Bo Y; Zhou F; Béland K; Bai X; Zeher AR; Huang RK; Nguyen DN; Sherburn R; Wu D; Piszczek G; Paré B; Matthies D; Xia D; Richard J; Kumar P; Mothes W; Côté M; Uchil PD; Lavallée VP; Smith MA; Pazgier M; Haddad E; Finzi A
    iScience; 2023 Jan; 26(1):105783. PubMed ID: 36514310
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron.
    Zhang L; Li Q; Liang Z; Li T; Liu S; Cui Q; Nie J; Wu Q; Qu X; Huang W; Wang Y
    Emerg Microbes Infect; 2022 Dec; 11(1):1-5. PubMed ID: 34890524
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
    Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
    mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern.
    Schmitz KS; Geers D; de Vries RD; Bovier TF; Mykytyn AZ; Geurts van Kessel CH; Haagmans BL; Porotto M; de Swart RL; Moscona A
    mBio; 2022 Jun; 13(3):e0124922. PubMed ID: 35695453
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern.
    Valanparambil R; Carlisle J; Linderman S; Akthar A; Millett RL; Lai L; Chang A; McCook A; Switchenko J; Nasti T; Saini M; Andreas Wieland AW; Manning K; Ellis M; Moore K; Foster S; Floyd K; Davis-Gardner M; Viswanadh Edara V; Patel M; Steur C; Nooka A; Green F; Johns M; O Brein F; Shanmugasundaram U; Zarnitsyna V; Ahmed H; Nyhoff L; Mantus G; Garett M; Edupuganti S; Behra M; Antia R; Wrammert J; Suthar M; Dhodapkar M; Ramalingam S; Ahmed R
    medRxiv; 2022 Jan; ():. PubMed ID: 35018383
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor.
    Andrade SA; Batalha-Carvalho JV; Curi R; Wen FH; Covas DT; Chudzinski-Tavassi AM; Moro AM
    Front Immunol; 2022; 13():871874. PubMed ID: 35898497
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
    Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
    J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.